OptiNose, Inc. (OPTN)
NASDAQ: OPTN · Real-Time Price · USD
9.17
+0.02 (0.22%)
Mar 31, 2025, 4:00 PM EDT - Market closed
OptiNose Revenue
In the year 2024, OptiNose had annual revenue of $78.23M with 10.20% growth. OptiNose had revenue of $22.42M in the quarter ending December 31, 2024, with 12.86% growth.
Revenue (ttm)
$78.23M
Revenue Growth
+10.20%
P/S Ratio
1.19
Revenue / Employee
$592,621
Employees
132
Market Cap
92.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78.23M | 7.24M | 10.20% |
| Dec 31, 2023 | 70.99M | -5.29M | -6.93% |
| Dec 31, 2022 | 76.28M | 1.62M | 2.18% |
| Dec 31, 2021 | 74.65M | 25.54M | 51.99% |
| Dec 31, 2020 | 49.12M | 14.49M | 41.83% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
OPTN News
- 10 days ago - OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN - Business Wire
- 10 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders - GlobeNewsWire
- 11 days ago - Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - GlobeNewsWire
- 11 days ago - Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 2 months ago - Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million - GlobeNewsWire
- 3 months ago - Optinose Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript - Seeking Alpha